Advertisement
Research Article| Volume 61, ISSUE 5, 103445, October 2022

Download started.

Ok

The determinants of donor safety and product quality in optimization of apheresis granulocyte harvest: An experience from a tertiary care oncology centre in India

Published:April 07, 2022DOI:https://doi.org/10.1016/j.transci.2022.103445
The determinants of donor safety and product quality in optimization of apheresis granulocyte harvest: An experience from a tertiary care oncology centre in India
Previous ArticleD or anti-D!!! Unblocking the dilemma of blocking-D phenomenon using acid elution
Next ArticleDonor safety in an individualized plasmapheresis program – Results of an interim analysis

      Abstract

      Allogeneic granulocyte transfusions play a substantial role in treatment of lifethreatening neutropenia-associated infections in patients undergoing intensive chemotherapy and hematopoietic stem cell transplant. Granulocyte harvest by apheresis is considered a safe and effective method to obtain adequate therapeutic granulocyte dosage for clinical effectiveness. This study described the experiences associated with apheresis granulocyte harvest procedures in our tertiary care haemato-oncology centre. We have analysed the incidence of adverse events (AEs) with associated potential risk factors contributing to donor safety and improvement in product quality. Retrospective data of 131 healthy allogeneic donors who underwent granulocyte harvest from May 2016 to July 2020 were analyzed. AEs were observed in overall 29 procedures (22.13%), including 14.50% citrate reactions, 7.6% venous access-related reactions, and 1.52% vasovagal reactions. Older age (p = 0.012) and higher body mass index (p = 0.015) in donors were significant variables found associated with a higher incidence of AEs. There was no significant impact of AEs on granulocyte product yield (p = 0.41) with a median collection yield of 1.73 × 10 10 cells/ unit. In multivariate analysis, post-mobilization parameters like total leukocyte counts (p = 0.036), absolute neutrophil counts (p = 0.042), and platelet counts (p = 0.006) showed a positive correlation with higher product yield. All the donors successfully donated and tolerated granulocyte colony stimulating factor plus dexamethasone mobilization and granulocyte apheresis harvest without any serious AEs. Our study shows that optimal technical and procedural modifications during apheresis granulocyte harvest procedures can overcome the associated potential risks by providing donor safety and improving product quality.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Pagano M.B.
        • Morton S.
        • Cohn C.S.
        • Gross S.
        • Kutner J.
        • Lewin A.
        • et al.
        An international registry of granulocyte transfusions.
        Transfus Med Hemotherapy. 2018; 45: 318-322https://doi.org/10.1159/000492629.Epub 2018 Aug 24
        View in Article
        • Brockmann F.
        • Kramer M.
        • Bornhäuser M.
        • Ehninger G.
        • Hölig K.
        Efficacy and side effects of granulocyte collection in healthy donors.
        Transfus Med Hemotherapy. 2013; 40 (Epub 2013 Jul 19): 258-264https://doi.org/10.1159/000354093
        View in Article

      3. Morton S, Stanworth S . INF 276/5 Revised Clinical guidelines for the use of granulocyte transfusions.:13. Granulocyte working group, NHS; Blood and Transplant; 2021. 〈https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/25196/clinical-guidelines-for-the-use-of-granulocyte-transfusions.pdf〉.

        View in Article
        • Lee J.-J.
        • Chung I.-J.
        • Park M.-R.
        • Kook H.
        • Hwang T.-J.
        • Ryang D.-W.
        • et al.
        Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections.
        Leukemia. 2001; 15: 203-207https://doi.org/10.1038/sj.leu.2402007
        View in Article
        • Simon T.L.
        • McCullough J.
        • Snyder E.L.
        • Solheim B.G.
        • Strauss R.G.
        Book: Rossi’s principles of transfusion medicine.
        fifth ed. John Wiley & Sons Inc, Chichester, West Sussex; Hoboken, NJ2016: 271-277 (1 p. Chapter 23. Neutrophil collection and transfusion)
        View in Article

      6. Estcourt LJ, Stanworth SJ, Doree C, Blanco P, Hopewell S, Trivella M, et al. Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane gynaecological, neuro-oncology and orphan cancer group, editor. cochrane database syst rev [Internet]; 2015 Jun 29 〈https://doi.wiley.com/10.1002/14651858.CD005341.pub3〉.

        View in Article
        • Price T.H.
        • Boeckh M.
        • Harrison R.W.
        • McCullough J.
        • Ness P.M.
        • Strauss R.G.
        • et al.
        Efficacy of transfusion with granulocytes from G-CSF/dexamethasone–treated donors in neutropenic patients with infection.
        Blood. 2015; 126 (Epub 2015 Sep2): 2153-2161https://doi.org/10.1182/blood-2015-05-645986
        View in Article
        • Suzanne A.
        • Arinsburg D.O.
        Transfusion Medicine and Hemostasis. Granulocyte products, Chapter 35.
        Elsevier Inc, 2013: 35 (http://dx.doi.org/10.1016.B978-0-12-397164-7.00035-5)
        View in Article
        • Wiles W.C.
        • Rodger E.
        • Dale D.C.
        Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
        Transfusion. 2000; 40: 40060642https://doi.org/10.1046/j.1537-2995.2000
        View in Article
        • David Stroncek Cynthia L.
        • Mathew Dean
        • Follman
        • Susan F.Leitman
        Kinetics of G-CSF induced granulocyte mobilization in healthy subjects.
        Transfusion. 2002; 42: 597-602https://doi.org/10.1046/j.1537-2995.2002.00091. x
        View in Article

      11. Marleen M. Neyrinck, Hans Vrielink: on behalf of “the Joint Task Force for Education and Certification”. Calculations in Apheresis. Journal of Clinical Apheresis; 2014: Wiley Periodicals, Inc. 〈https://doi.org/10.1002/jca.21347〉.

        View in Article
        • Worel Nina
        • Kurz Martin
        • Peters Christina
        • Hocker Paul
        Serial granulocytepheresis under daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield.
        Transfusion. 2001; 41https://doi.org/10.1046/j.1537-2995.2001.41030390. x
        View in Article

      13. Lise J. Estcourt, Simon J. Stanworth, Sally Hopewell, Carolyn Doree, Marialena Trivella and Edwin Massey. Cochrane Database Syst Rev.;4: CD005339. 〈https://doi.org/10.1002/14651858.CD005339.pub2〉.

        View in Article

      14. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. U.S. Department of Health and Human services; 2017:155. 〈https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf〉.

        View in Article
        • Ikemoto J.
        • Yoshihara S.
        • Fujioka T.
        • Ohtsuka Y.
        • Fujita N.
        • Kokubunji A.
        • et al.
        Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy: collection methods and granulocyte yield.
        Transfusion. 2012; 52: 2646-2652https://doi.org/10.1111/j.1537-2995.2012.03661. x. Epub 2012 Apr 23
        View in Article

      16. Benjamin J., Greco, Bet H. Shaz. Adverse donor reactions, Transfusion Medicine and Hemostasis (Second Edition); 2013. 〈https://doi.org/10.1016/B978-0-12-813726-0.00008-8〉.

        View in Article
        • Miguel Angel Rodriguez-Calero
        • Ian Blanco-Mavillard
        • Jose Miguel Morales-Asencio
        • Ismael Fernandez-Fernandez
        • Enrique Castro-Sanchez
        • Joan Ernest de Pedro-Gomez
        Defining risk factors associated with peripheral venous cannulation: a systematic review and meta-analysis.
        Heart & Lung. 2020; 49 (Epub 2020 Feb 11): 273-286https://doi.org/10.1016/j.hrtlng.2020.01.009
        View in Article

      18. Sheppard Chelsea A, Hillyer Cristopher D. Therapeutic apheresis in Consultative hemostasis and Thrombosis (Second Edition); 2007. 〈https://doi.org/10.1016/B978-1-4160-2401-9.X1000-0〉.

        View in Article
        • Pagliariccio A.
        • Vavic N.
        • Bulajic M.
        • Marinozzi M.
        P-14; is there a causal link between anxiety and vasovagal reactions?.
        Transfus Apher Sci. 2012; 47: S28https://doi.org/10.1016/S1473-0502(12)70050-2
        View in Article
        • Karen Quillen Yu.Ying Yau
        • Susan F.Leitman
        The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience.
        Transfusion. 2009; 49 (x. Epub 2008 Nov 19): 421-426https://doi.org/10.1111/j.1537-2995.2008.01997
        View in Article
        • Weingarten Christina
        • Pliez Sarah
        • Tschiedel Eva
        • et al.
        Granulocyte transfusions in critically ill children with prolonged neutropenia: side effects and survival rates from a single-center analysis.
        Eur J Pediatr. 2016; 175 (Epub 2016 Sep 8): 1361-1369https://doi.org/10.1007/s00431-016-2774-y
        View in Article

      Article info

      Publication history

      Published online: April 07, 2022
      Accepted: April 5, 2022
      Received in revised form: April 2, 2022
      Received: February 10, 2022

      Identification

      DOI: https://doi.org/10.1016/j.transci.2022.103445

      Copyright

      © 2022 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX